Castle Biosciences, Inc.

Castle Biosciences, Inc. Beats on EPS, Stock Down 2.79%

Castle Biosciences reported a narrower-than-expected loss per share, which is a positive surprise. However, the stock fell by 2.79% in reaction, indicating that investors may have had lower expectations or concerns about other aspects of the company's performance. The lack of revenue figures and guidance may have contributed to the stock's decline.